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ABSTRACT 
Inhibition of DNA repair is an attractive therapeutic approach to enhancing the 
activity of DNA-damaging anticancer chemotherapeutic agents. Similarly, blockade 
of the multidrug-resistance protein 1 (MDR1) can overcome efflux-mediated 
resistance. DNA-dependent protein kinase (DNA-PK) is essential for the non-
homologous end-joining DNA repair pathway. NU7441 is a potent DNA-PK inhibitor 
(IC50 = 14 nM) that is used widely to study the effects of DNA-PK inhibition in vitro. In 
growth inhibition studies, 1 μM NU7441 sensitised vincristine-resistant CCRF-CEM 
VCR/R leukaemia cells (1200-fold resistant) to a range of MDR1 substrates, 
including doxorubicin (8-fold, p=0.03), vincristine (14-fold, p=0.01) and etoposide 
(63-fold, p=0.02), compared with 1.4-fold (p=0.02), 2.2-fold (p=0.04) and 3.6-fold 
(p=0.01) sensitisation, respectively, in parental CCRF-CEM cells. A doxorubicin 
fluorescence assay showed that in MDR1-overexpressing canine kidney MDCKII-
MDR1 cells, 1 µM NU7441 increased doxorubicin nuclear fluorescence 16-fold. 
NU7441 and 3 structurally-related compounds (NU7742 (an NU7441 analogue that 
does not inhibit DNA-PK - IC50>10 μM), DRN1 (DNA-PK-inhibitory atropisomeric 
NU7441 derivative - IC50=2 nM) and DRN2 (DNA-PK non-inhibitory atropisomeric 
NU7441 derivative - IC50=7 μM)) all increased intracellular vincristine accumulation in 
the CCRF-CEM VCR/R cells to a level similar to verapamil, as measured by LC-MS. 
However, the non-inhibitory compound NU7742 was 5-fold less effective at 
sensitising CCRF-CEM VCR/R cells to vincristine than NU7441 (p=0.008). This 
paper demonstrates that NU7441 is a dual DNA-PK and MDR1 inhibitor, and this 
extends the therapeutic potential of the compound when used in combination with 
MDR substrates.  
KEYWORDS: DNA-PK, MDR1, NU7441, cancer, multidrug resistance  
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1. INTRODUCTION 
DNA is the main target of many conventional anticancer agents and therefore the 
inhibition of DNA repair is an attractive approach to chemosensitisation. DNA 
double-strand breaks are the most lethal type of DNA damage and therefore two 
major pathways have evolved to repair these DNA lesions; homologous 
recombination (HR) and non-homologous end-joining (NHEJ). DNA-PK is a 
serine/threonine protein kinase and is a member of the phosphatidylinositol 3-kinase 
like kinase (PIKK) family. DNA-PK is essential for the NHEJ repair pathway [1], and 
has also been implicated in HR [2], H2AX phosphorylation [3], metabolic gene 
regulation [4], and in the inflammatory response through interactions with NFκB [5].  
NU7441 (8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one, Fig. 1(a)) is a 
potent ATP-competitive DNA-PK inhibitor (IC50 = 14 nM) developed from the 
phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 [6]. NU7441 has been 
shown to increase sensitivity to radiation and topoisomerase II poisons, and increase 
etoposide-induced tumour growth delay in mice bearing SW620 xenografts [7]. 
NU7441 is around 20-fold more selective for cellular DNA-PK over PI3K inhibition 
[8]. NU7742 (8-dibenzothiophen-4-yl-2-piperidin-1-yl-chromen-4-one, Fig. 2(a)) is an 
inactive derivative of NU7441 (IC50 > 10 µM) in which the morpholine oxygen has 
been replaced with a methylene group, resulting in the loss of sensitisation of cells to 
DNA-damaging agents [9]. The introduction of a methyl substituent at the 7-position 
of the chromen-4-one ring generated atropisomers DRN1 (DNA-PK IC50 = 2 nM) and 
DRN2 (DNA-PK IC50 = 7 µM) (Fig. 1(c)).  As expected and due to restricted rotation 
between the chromen-4-one and dibenzothiophene rings, the DNA-PK inhibitory 
activity resides exclusively in the laevorotatory enantiomer DRN1 [10]. 
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MDR1/P-glycoprotein (the product of the ABCB1/MDR1 gene) was the first member 
of the (ATP)-binding cassette (ABC) superfamily of transmembrane transporters to 
be cloned, and is known to play a significant role in the multidrug-resistance (MDR) 
phenotype in cancer cells [11]. MDR1 is a 170 kDa protein located in the apical 
membrane of many cell types which acts as a drug efflux transporter in the liver, 
kidneys, gastrointestinal tract, and multiple blood barriers including the blood-brain 
and the blood-placental barriers [12, 13]. MDR1 is known to play a role in conferring 
resistance to a number of anticancer agents, including the vinca alkaloids, taxanes 
and anthracyclines [14].  
Verapamil, a calcium channel blocker used clinically as a coronary vasodilator, was 
amongst the first compounds identified that could reverse MDR and potentiate the 
effects of MDR1 substrates such as vincristine [15, 16]. Verapamil, along with a 
number of other MDR1 blockers, have proved largely unsuccessful in clinical trials 
due to toxicity or side effects [17].  
Recently, there have been a number of publications reporting that targeted 
anticancer therapies also reverse MDR by inhibiting the efflux functions of the ABC 
family of transporters, including ABCB1 (MDR1). Thus the kinase inhibitors imatinib 
and nilotinib (BCR-Abl inhibitors) [18], gefitinib, erlotinib and lapatinib (EGFR 
inhibitors) [19-21], apatinib (VEGFR2 inhibitor) [22], and sorafenib (Raf-targeting 
drug) [23] have all been shown to be potent inhibitors of ABCB1. 
Following observations that the DNA-PK inhibitor NU7441 caused greater 
sensitisation to cytotoxic agents in MDR1-overexpressing versus non-
overexpressing cells, this study aimed to investigate whether NU7441 was 
interacting with drug efflux via MDR1.  
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2. MATERIAL AND METHODS 
 
2.1. Chemicals 
All chemicals were obtained from Sigma-Aldrich (UK) unless stated otherwise and all 
solvents and solutions for HPLC were obtained from Fisher Scientific (UK). DNA-PK 
inhibitors were provided by the NICR Medicinal Chemistry group and synthesised as 
previously described [9, 10]. NU7441 and NU7742 were dissolved at 2 mM in 
DMSO. DRN1 and DRN2 were dissolved at 1.5 mM in DMSO. The structures of 
NU7441, NU7742, DRN1 and DRN2 are shown in Figure 1. All solutions were stored 
at -20 °C. 
2.2. Cell lines 
The CCRF-CEM acute lymphoblastic leukaemia cell line and the vincristine-resistant 
derivative, CCRF-CEM VCR/R, cells were used. The CCRF-CEM cells (85112105 
(ECACC)) have been previously authenticated. The CCRF-CEM VCR/R cells were 
developed by stepwise exposure to increasing concentrations of vincristine [24] and 
display overexpression of P-glycoprotein and multidrug resistance. Cells were 
maintained as a suspension culture in RPMI 1640 medium supplemented with 10 % 
(v/v) foetal calf serum (Gibco, UK), penicillin (50 units/ml) and streptomycin (50 
μg/ml). 
The MDCKII and MDCKII-MDR1 cells were obtained from Alfred Schinkel 
(Netherlands Cancer Institute). These cells are a Madin-Darby canine kidney strain II 
cell line, the MDCKII-MDR1 subline overexpresses the human MDR1 gene due to 
transfection [25]. The MDCKII and MDCKII-MDR1 cells were maintained in DMEM 
supplemented with 10 % (v/v) foetal calf serum (Gibco, UK), 1 % (w/v) glutamine, 
penicillin (50 units/ml) and streptomycin (50 μg/ml). 
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All cells lines were maintained at 37 °C in a 5 % CO2 atmosphere and were routinely 
screened for mycoplasma and used when under the 30th passage from frozen 
stocks. 
2.3. Protein extraction and Western blotting 
Whole cell extracts were treated with ice-cold Phosphosafe extraction reagent 
(Merck, UK) containing protease inhibitor (Roche, UK), centrifuged and supernatants 
were kept at −80 °C until protein quantification. Gel electrophoresis was carried out 
with 3–8 % (w/v) tris–acetate XT-criterion gels (Biorad, UK), and blotting was 
performed on nitrocellulose membranes (Hybond C Extra, Amersham Biosciences, 
UK). Membranes were blocked for 1 hour (TBS-T containing 5 % (w/v) BSA for 
phosphorylated proteins or 5 % (w/v) milk for total proteins) followed by 4 °C 
overnight incubation with primary antibodies against actin (CP01, Calbiochem, UK), 
pSer2056 DNA-PKcs (Ab18192, Abcam, UK), total DNA-PKcs (sc-9051, Santa Cruz 
Biotechnology, USA) or MDR1 (SC-13131, Santa Cruz Biotechnology, USA). 
Membranes were then washed in TBS-T and incubated with HRP-conjugated 
secondary antibodies (goat anti-mouse, code P0447 and goat anti-rabbit, code 
P0448, Dako, UK) and visualised using ECL reagent (Amersham Biosciences, UK). 
Images were acquired using Kodak X-ray film (Carestream Health, USA) on 
MediPhot 937 film developer, (Colenta, Austria) then digitally scanned. Quantification 
was undertaken by image acquisition of the films and densitometry analysis with a 
Fuji LAS-3000 Luminescent Image Analyzer (Raytek, UK). Data are displayed 
relative to actin loading control. 
2.4. Quantitative real-time PCR 
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CCRF-CEM and CCRF-CEM VCR/R cell pellets were collected and the total RNA 
was purified using RNeasy Mini kit (Qiagen, UK). The RNA was then reverse 
transcribed using Quantitect RT kit (Qiagen, UK) and real time PCR was performed 
on 40ng cDNA using Taqman Gene Expression assays (ABCB1 assay ID: 
Hs00184500_m1, Beta-actin assay ID: Hs99999903_m1) and Taqman PCR master 
mix (Applied Biosystems, UK). The samples were run and analysed on a 7500 Fast 
Real Time PCR system (Applied Biosystems,UK). Results are displayed as ΔCT, 
which is the cycle threshold of ABCB1 normalised to β-actin, and the relative quantity 
(RQ) of ABCB1. 
2.5. XTT cytotoxicity assay 
The XTT assay (Roche, Germany) was carried out following the manufacturer’s 
instructions. After 72-hour drug treatment, 50 µl XTT assay reagent mix was added 
to each well in a 96-well plate, which was then incubated for 4 hours at 37 °C and 5 
% CO2 after which the absorbance was measured at 450 nm using a FLUOstar 
Omega plate reader (BMG Labtech, Germany). Growth of drug-treated cells was 
expressed as a percentage of control cell growth. Fold sensitisation was calculated 
using the GI50 values of each treatment.  
2.6. Doxorubicin nuclear fluorescence assay 
Doxorubicin is a fluorescent P-glycoprotein substrate (λ ex: 470 nm, λ em: 595 nm). 
MDCKII and MDCKII-MDR1 cells were seeded in black, clear-bottomed 96-well 
plates (Greiner Bio-One, UK) and incubated for 3 days. Cells were then incubated for 
1 hour with varying concentrations of NU7441 (0-10 µM), verapamil (0-10 µM) or 
cisplatin (10 µM). Following incubation, 10 µM doxorubicin was added for a further 1 
hour. Cells were then washed in PBS and fixed with 10 % (v/v) formalin in PBS for 
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20 minutes. Cells were stained with DAPI for 20 minutes, washed again and 200 µl 
PBS was added. Nuclear doxorubicin content was measured by fluorescence on a 
BD Pathway HT microscope (BD Biosciences, UK). Excitation was at 488 nm and a 
515 nm long-pass filter was used to collect emitted fluorescence. Arbitrary 
fluorescence data was collected from >1000 cells in 3 separate experiments and the 
doxorubicin concentration was calculated as a percentage of the doxorubicin control-
treated cells.  
2.7. Sample Preparation for LC-MS analysis 
CCRF-CEM and CCRF-CEM VCR/R cells were seeded into 6 well plates for 24 
hours at a density of 1 x 106 cells/ml. The cells were then incubated for 1, 8, or 24 
hours in the presence of vincristine alone at equitoxic GI50 concentrations (1 nM in 
CCRF-CEM cells and 1 µM in the CCRF-CEM VCR/R cells) or in the presence of 1 
µM of NU7441, NU7742, DRN1, DRN2 or verapamil. Cells were centrifuged for 5 
minutes and washed in PBS twice to remove all trace of media. 400 µl 100 % 
methanol was added and the cells were centrifuged at 16000 x g for 5 minutes. The 
methanol solution was transferred to glass vials and stored in a -20 ºC freezer until 
analysed. Standard curves for vincristine (0.01-3 µM), NU7441 and verapamil 
(0.003-1 μM) were prepared in methanol.  
2.8. Liquid Chromatography-Mass Spectrometry  
Analysis of samples was carried out using a liquid chromatography–mass 
spectrometry (LC–MS) assay validated in house based on a previously described 
method [26]. An API4000 LC/MS/MS (Applied Biosystems, USA) was used for 
analysis, with an LC-200 Micro pump, autosampler and Peltier column oven (Perkin 
Elmer, UK). The analytical column used was a Phenomenex Luna 3µ C8 (2), 50 x 2 
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mm, (PNo. 00B-4248-B0, Phenomenex, UK) maintained at 30 °C. Elution of the 
analytes was performed with mobile phases of 0.02 M ammonium acetate pH 5 
(pump A) and 100 % methanol (pump B). The analysis was performed using the 
gradient shown in Table 1, at a flow rate of 400 µl/min, and an injection volume of 10 
µl. Atmospheric Pressure Chemical Ionisation was performed in positive ion mode 
using nitrogen gas with the following optimum settings: collision gas, 9; curtain gas, 
10; ion source gas 1, 21; ion source gas 2, 45 (settings in Table 2). The temperature 
of the heated nebulizer was 450 °C. Analyst® software v1.5 (AB SCIEX, USA) was 
used for sample analysis, peak integration and analyte quantitation. 
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3. RESULTS 
 
3.1. NU7441 sensitises MDR1-overexpressing multidrug resistant cells 
to a range of MDR1 substrates 
Growth inhibition assays were used to investigate the effect of drug combinations on 
the growth of CCRF-CEM and CCRF-CEM VCR/R cells. The CCRF-CEM VCR/R 
cells are multidrug-resistant (MDR) through overexpression of the drug efflux 
transporter, MDR1, as shown in Fig. 2(a), (b) and (c). The CCRF-CEM VCR/R cells 
were approximately 1200-fold (p=0.01) resistant to vincristine compared to the 
sensitive CCRF-CEM cells (Fig. 2(e)) and this large difference in sensitivity is the 
reason that these cell lines were selected for these experiments (GI50 values in Table 
3). The CCRF-CEM VCR/R cells were also cross-resistant to doxorubicin (52-fold 
resistant (p=0.02)) (Fig. 2(f)) and etoposide (150-fold resistant (p=0.02)) (Fig. 2(g)). 
The DNA-PK inhibitor NU7441 used at 1 µM did not cause any growth inhibition 
alone in either cell line and both the CCRF-CEM and CCRF-CEM VCR/R cells 
showed the same growth inhibition profile in response to increasing concentrations 
of the DNA-PK inhibitor (Fig. 2(d)). NU7441 sensitised the CCRF-CEM VCR/R cells 
14-fold to vincristine (p=0.01), 8-fold to doxorubicin (p=0.03) and 63-fold to etoposide 
(p=0.02), compared with 1.4-fold (p=0.02), 2.2-fold (p=0.04) and 3.6-fold (p=0.01), 
respectively, in the CCRF-CEM cells (Figs. 2(e) (f) (g)). These observed differences 
in sensitisation by NU7441 in the parental and vincristine-resistant CCRF-CEM cells 
to cytotoxic agents that are all known MDR1 substrates led us to the hypothesis that 
NU7441 interacts with MDR1. 
3.2. NU7441 interacts with MDR1 
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The Madin-Darby canine kidney II (MDCKII) cells and their MDR-1-overexpressing 
counterpart, MDCKII-MDR1 cells, were used in this experiment (Fig, 3(a)) because 
the doxorubicin fluorescence assay must be carried out on adherent cells. 
Doxorubicin is a fluorescent cytotoxic MDR1 substrate and this assay measured 
doxorubicin fluorescence in the nucleus. There was less doxorubicin detectable in 
the MDCKII-MDR1 cells compared with the MDCKII cells, reflecting the greater efflux 
of doxorubicin by MDR1. There was a concentration-dependent increase in 
doxorubicin fluorescence with the addition of the competitive MDR1 substrate, 
verapamil, up to 1.6-fold increase at 10 µM verapamil (Fig. 3(c)). There was also a 
concentration-dependent increase in nuclear doxorubicin accumulation, i.e. inhibition 
of efflux, with the addition of NU7441 to a level similar to that seen with verapamil 
(Figs. 3(c) and (d)). There was a significant 1.2-fold increase in doxorubicin 
fluorescence at 1 µM NU7441, which is the concentration previously shown to be 
optimal for DNA-PK inhibition with no cellular toxicity [7]. In contrast to the MDCKII-
MDR1 cells there was no significant change in doxorubicin fluorescence with either 
verapamil or NU7441 in the MDCKII cells (Fig. 3(b)), consistent with the effect seen 
in the MDCKII-MDR1 cells being due to NU7441 interacting with MDR1 to block the 
efflux of doxorubicin from these cells. 
3.3. The effect of NU7441, NU7742 and two structural atropisomeric 
derivatives of NU7441 on DNA-PK activity in CCRF-CEM cells 
Following the observation that NU7441 was interacting with MDR1, it was necessary 
to determine if the effect of NU7441 was direct or mediated by DNA-PK inhibition. It 
is known that the morpholine group is necessary for DNA-PK inhibitory activity of 
NU7441 (DNA-PK IC50 = 14 nM) (Fig. 1(a)) [27] as replacement of the morpholine 
oxygen with a methylene group results in loss of DNA-PK inhibitory activity as seen 
12 
 
with NU7742 (DNA-PK IC50 > 10 µM) (Fig. 1(b)). Two atropisomeric derivatives of 
NU7441, DRN1 and DRN2 (Fig. 1(c)) were used in these studies [10]. Introduction of 
a methyl substituent at the 7-position of the chromen-4-one ring restricts rotation 
between the dibenzothiophene and the chromenone rings causing atropisomerism. 
DRN1 is the laevorotatory enantiomer, showing high potency against DNA-PK (IC50 
= 2 nM) (Fig. 1(c) (i)), whereas the dextrorotatory enantiomer, DRN2, has markedly 
reduced inhibitory activity (IC50 = 7 µM) (Fig. 1(c) (ii)).   
Figure 4 shows the DNA-PK-inhibitory properties of NU7441 and the derivatives in 
the CCRF-CEM and CCRF-CEM VCR/R cells as measured by Western blotting (Fig. 
4(a) and (b)). Both the sensitive and MDR cells have basal DNA-PK activity as 
demonstrated by detection of DNA-PK phosphorylated at serine 2056, a site of DNA-
PK autophosphorylation. Cells were treated with GI50 vincristine concentrations both 
alone and in combination with NU7441, NU7742, DRN1, DRN2 and verapamil. 
NU7441 and DRN1 markedly inhibited DNA-PK activity in both cell lines (Fig. 4(c) 
and (d)), whereas NU7742, DRN2 and verapamil had no effect on DNA-PK 
phosphorylation. 
3.4. Both DNA-PK inhibitory and non-inhibitory compounds increase 
intracellular vincristine levels in MDR cells 
Following the observation that NU7441 interacts with MDR1, as shown by the 
doxorubicin efflux fluorescence microscopy data in the MDCKII cells treated with 
doxorubicin, this effect was further investigated using a more quantitative approach. 
The CCRF-CEM and CCRF-CEM VCR/R cells were treated with the MDR1 
substrate vincristine alone and in combination with the compounds using the 
conditions described in Fig. 4. None of the compounds altered vincristine 
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concentration in the CCRF-CEM cells after 1 or 8 hours drug exposure (Fig. 5(a)). In 
contrast, in the CCRF-CEM VCR/R cells, all of the compounds tested increased the 
intracellular vincristine level when compared with vincristine alone at both 1 and 8 
hours, consistent with an inhibition of vincristine efflux (Fig. 5(b)). At the 
concentration tested (1 µM), NU7441 induced the highest vincristine accumulation at 
both 1 hour (1.3-fold; p=0.01) and 8 hours (2.1-fold; p=0.04), i.e. to a level similar to 
that induced by verapamil. NU7742 did not increase intracellular vincristine to the 
same degree as NU7441 (1.5-fold at 8 hours), showing that the morpholine group 
may play a role in the interaction of NU7441 and MDR1. Both DRN1 and DRN2 
increased intracellular vincristine to the same degree (1.4-fold) after 8 hours, 
although they did not block vincristine efflux to the same degree as NU7441.  
It was also possible to measure the intracellular levels of both verapamil and 
NU7441 in the CCRF-CEM and CCRF-CEM VCR/R cells. There was no change 
between 1 and 8 hours in the levels of these compounds in the CCRF-CEM cells 
(data not shown). In the CCRF-CEM VCR/R cells, there was no significant change in 
intracellular verapamil concentrations after 8 hours (Fig. 5(c)). There was however a 
significant increase in intracellular NU7441 levels at 8 hours, suggesting 
accumulation (Fig. 5(d)). 
Overall, the data in Figure 5 demonstrate that inhibition of vincristine efflux by 
NU7441 and its derivatives is independent of their activity as DNA-PK inhibitors.  
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4. DISCUSSION 
It is known that many conventional cytotoxic anticancer drugs are transported out of 
the cell by MDR1, and it has been shown that MDR1 affects both the intracellular 
accumulation and intra-tumour distribution of compounds [28]. The importance of the 
ABC transporter family has been somewhat overlooked in the development of more 
targeted therapies but a number of recent publications have demonstrated that 
targeted therapies can interact with this family of transporters [18-23, 29]. 
Understanding the role of drug efflux transporters is key when investigating 
combinations of targeted therapies with drugs that are MDR1 substrates.  
Inhibition of DNA repair, particularly of double-strand break repair pathways, is an 
emerging therapeutic strategy in cancer treatment.  In the preclinical setting, DNA-
PKcs overexpression has been shown in chronic lymphocytic leukaemia patients 
with del(17p) (associated with p53 mutation) or del(11q) (associated with ATM 
mutation) chromosomal aberrations and associated with poor prognosis [9]. In 
addition, enhanced metastasis and poorer prognosis has been observed in patients 
with lower DNA-PK activity in their peripheral blood lymphocytes [30]. Furthermore, 
in response to DNA-damaging agents, ATM-defective cells are prevented from 
undergoing apoptosis and display a strong non-oncogenic addiction to DNA-PKcs 
[31]. Inhibition of DNA-PK means the ATM-deficient cells cannot repair double-strand 
breaks and leads to apoptosis and DNA-PK inhibitors have been shown to be an 
effective monotherapy in ATM-defective lymphomas in vivo [31]. 
NU7441 is a potent inhibitor of DNA-PK. During investigations of the effect of 
NU7441 on the activity of a range of chemotherapeutic agents in both parental and 
multidrug-resistant cells, it was noted that NU7441 sensitised the multidrug-resistant 
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CCRF-CEM VCR/R cells to vincristine, doxorubicin and etoposide and to a greater 
degree than in parental CCRF-CEM cells. The CCRF-CEM VCR/R cells are resistant 
to vincristine via overexpression of the efflux transporter MDR1 following stepwise 
treatment with increasing concentrations of vincristine. Therefore, a potential 
interaction between NU7441 and MDR1 was hypothesised.  
Initially, the doxorubicin fluorescence assay demonstrated that NU7441 induces 
doxorubicin accumulation in a concentration-dependent manner in paired wild-type 
and MDR1-overexpressing MDCKII cells. The kinase inhibitor sorafenib is used to 
treat advanced renal cell carcinoma [32] and hepatocellular carcinoma [33], and 
MDR1 has been shown to play a major role in the acquired resistance phenotype in 
hepatocellular carcinoma [34]. Furthermore sorafenib has been shown to reverse 
paclitaxel resistance in MDR cells and cause a concentration-dependent increase in 
the uptake and retention of rhodamine 123; suggesting that sorafenib inhibits MDR1 
[23]. Thus the data with NU7441 are consistent with those for sorafenib. 
To investigate whether drug accumulation induced by NU7441 was linked to DNA-
PK inhibition, a range of NU7441 derivatives with different DNA-PK inhibitory 
properties were studied. All of the compounds investigated increased intracellular 
vincristine concentration, as shown by LC-MS, in the MDR1-overexpressing CCRF-
CEM VCR/R cells regardless of their DNA-PK-inhibitory activity.  
Compounds that interact with MDR1 can do so by different mechanisms. Verapamil 
is known to modulate drug resistance by acting as a competitive MDR1 substrate 
[35]. However, the data presented here indicate that NU7441 does not act as a 
competitive substrate but rather as an inhibitor of MDR1. Thus NU7441 has similar 
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growth inhibitory activity in the sensitive and resistant cells and there was no 
observed reduction in intracellular levels of NU7441 over time (Figures 1(c) and 5).  
Although the clinical relevance of MDR1 expression in solid tumours remains 
controversial, MDR1 has been shown to be relevant to acquired drug resistance in 
haematological cancers [36]. MDR is a biomarker for poor prognosis in patients with 
haematological cancers who can be cross-resistant to standard chemotherapeutic 
agents that are MDR1 substrates. The MDR substrates doxorubicin, etoposide and 
vincristine are used clinically in the treatment of haematological malignancies, such 
as acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) [37-39]. 
NU7441, in its capacity as a DNA-PK inhibitor, has been shown to sensitise cells to 
mitoxantrone, doxorubicin (in vitro) and etoposide (in vitro and in vivo) [7, 9], and this 
study has demonstrated that NU7441 can sensitise CCRF-CEM cells to vincristine.  
In conclusion, this study highlights the role of NU7441 as a dual DNA-PK and MDR1 
inhibitor, and this extends the therapeutic potential of the compound in combination 
with MDR substrates to sensitise both parental and MDR phenotypes.  
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Table 1: Gradient conditions of the HPLC mobile phase 
  
Step Total Time (min) A (%) B (%)
0 0.0 80 20
1 2.0 80 20
2 7.0 10 90
3 7.5 80 20
4 11.0 80 20
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Table 2: Mass transitions and optimised MS/MS parameters for vincristine analysis  
  
Analyte
Retention 
Time (mins)
Q1 Mass 
(Da)
Q3 Mass 
(Da)
Declustering 
Potential
Entrance 
Potential
Collision 
Energy
Collision 
Exit 
Potential
Vincristine 6.58 825.39 765.4 101 10 49 26
Verapamil 6.37 455.23 164.7 91 10 41 10
NU7441 7.64 414.01 247.1 91 10 67 6
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Table 3: GI50 values calculated from the growth inhibition curves of the CCRF-CEM 
and CCRF-CEM VCR/R cells treated with vincristine, doxorubicin, etoposide or 
NU7441 alone or vincristine, doxorubicin, etoposide in the presence of 1μM NU7441. 
GI50 values were calculated from three independent experiments and are displayed 
as mean ± standard error. Significant differences between CCRF-CEM cells treated 
with drug alone and the CCRF-CEM VCR/R cells treated with drug alone were 
calculated using an unpaired t-test shown as subscript. Significant differences 
between cells treated with drug alone and cells treated with drug + NU7441 were 
calculated using an unpaired t-test shown as superscript. ns = non-significant. 
  
Drug [μM] Drug + NU7441 [μM] Drug [μM] Drug + NU7441 [μM]
Vincristine GI50 0.0005 ± 0.02 0.0003 ± 0.03
p=0.02 0.61 ± 134p=0.01 0.043 ± 13.0
p=0.01
Doxorubicin GI50 0.04 ± 0.01 0.02 ± 0.002
p=0.04 2.03 ± 0.53p=0.02 0.26 ± 0.04
p=0.03
Etoposide GI50 0.33 ± 0.04 0.10 ± 0.03
p=0.01 48.4 ± 12.5p=0.02 0.93 ± 0.38
p=0.02
NU7441 GI50 4.07 ± 0.27 - 3.66 ± 0.26ns -
CCRF-CEM CCRF-CEM VCR/R
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Figure 1: The chemical structures and DNA-PK-inhibitory activity of (a) NU7441, (b) 
NU7742, and (c) the atropisomers of NU7441, DRN1 and DRN2. 
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Figure 2: MDR1-overexpressing CCRF-CEM VCR/R cells were sensitised to MDR1 
substrates to a greater degree by NU7441 when compared with parental CCRF-
CEM cells. (a) CCRF-CEM and CCRF-CEM VCR/R cell lysates were prepared and 
MDR1 expression determined by Western blot. (b) Quantification of 3 independent 
Western blots of MDR1 protein level represented as fold increase relative to CCRF-
CEM cells. (c) Taqman real-time PCR of CCRF-CEM and CCRF-CEM VCR/R cells 
examining ABCB1 mRNA expression. ΔCT is the cycle threshold of ABCB1 
normalised to β-actin, as determined using the 7500 Fast RT PCR system. Relative 
quantity (RQ). CCRF-CEM (solid line) and CCRF-CEM VCR/R (dotted line) cells 
treated with (d) increasing concentrations of NU7441 or (e) vincristine, (f) 
doxorubicin or (g) etoposide alone (open symbols) or in the presence of 1 µM 
NU7441 (solid symbols) for 72 hours and growth inhibition analysed by XTT assay. 
The growth data are presented as a percentage of untreated control cells. Each point 
represents 3 independent experiments, each in triplicate ± standard error.
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Figure 3: NU7441 interacts with MDR1 to block doxorubicin efflux in MDR1-
overexpressing MDCKII-MDR1 cells. (a) MDCKII and MDCKII-MDR1 cell lysates 
were prepared and MDR1 expression determined by Western blot. (b) and (c) 
MDCKII and MDCKII-MDR1 cells were treated with 0.1, 0.5, 1, 5, 10 μM verapamil 
(striped) or NU7441 (checked) for 1 hour followed by 10 µM doxorubicin (DOX) 
treatment for 1 hour. Cells were fixed, DAPI stained, and DOX nuclear fluorescence 
detected on a BD Pathway HT microscope. Results are means ± standard error of 
three independent experiments. Asterisk indicates a statistically significant difference 
(P < 0.05). (d) Representative images of MDCKII-MDR1 cells showing DAPI (blue) 
and doxorubicin (red) fluorescence. 
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Figure 4: Effect of NU7441, NU7742, DRN1 and DRN2 on vincristine-induced DNA-
PK activation. (a) CCRF-CEM and (b) CCRF-CEM VCR/R cells were treated for 8 
hours with GI50 concentrations of vincristine alone (Vinc) or in combination with 1 µM 
NU7441, NU7742, DRN1, DRN2 or verapamil. Western blot shows DNA-PK 
activation (phosphorylation at Serine 2056) in response to vincristine and the effects 
of the compounds on DNA-PK activation. Representative blots of three independent 
experiments. (c) and (d) Quantification of 3 independent Western blots for GI50 Vinc, 
NU7441 and NU7742 and 2 independent experiments for DRN1, DRN2 and 
verapamil displayed as a fold change in pDNA-PK level relative to the level in cells 
treated with GI50 Vinc alone. 
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Figure 5: Both DNA-PK inhibitory and non-inhibitory NU7441 derivatives increase 
intracellular vincristine levels in MDR cells. (a) CCRF-CEM and (b) CCRF-CEM 
VCR/R cells were treated for 1 or 8 hours with GI50 concentrations of vincristine 
(VCR) alone or in combination with 1 µM NU7441, NU7742, DRN1, DRN2 or 
verapamil. Intracellular vincristine levels were measured using LC-MS. CCRF-CEM 
VCR/R intracellular levels of (c) verapamil and (d) NU7441 also measured using the 
same LC-MS method. Results are means ± standard error of three independent 
experiments. Asterisk indicates a statistically significant difference in fold change 
relative to 1 hour VCR treatment alone (P < 0.05). 
 
 
 
